Home > Oncology > WCLC 2018 > Presidential Symposium – Top 5 abstracts > New standard of care in extensive-stage small-cell lung cancer

New standard of care in extensive-stage small-cell lung cancer

Presented By
Dr Stephen Liu, Georgetown University Hospital, USA
Conference
WCLC 2018
Trial
IMpower133
For nearly 4 decades, there has been little change in median OS in extensive-stage small-cell lung cancer (ES-SCLC) with 1L carboplatin and etoposide. Until now. The global, randomised, controlled phase 1/3 IMpower133 trial demonstrated that adding atezolizumab to carboplatin/etoposide resulted in significantly longer OS and PFS than treatment with chemotherapy alone. Dr Stephen Liu (Georgetown University Hospital, USA) presented results at WCLC 2018, which were simultaneously published in the New England Journal of Medicine [10]. IMpower133 evaluated atezolizumab plus 1L carboplatin and etoposide in treatment-naïve patients with ES-SCLC and ECOG performance status of 0 to 1. Atezolizumab is a humanised, monoclonal, anti-PD-L1 antibody that inhibits PD-1 and B7 signalling and restores tumour-specific T-cell immunity [11]. Patients were randomised 1:1 to receive four 21-day cycles of carboplatin and etoposide with either atezolizumab (n=201) or p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on